J&J scoops up another atopic dermatitis antibody in $1.25B Numab rights deal

Not satisfied with just one new immunology deal this month, Johnson & Johnson is plunking down $1.25 billion in cash to scoop up rights to Numab Therapeutics’ phase 2-ready atopic dermatitis bispecific antibody.